Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Torkinib
Cat. No.:
OB0225LY-0476
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Torkinib is an inhibitor that targets the TOR signaling pathway and affects cell proliferation and growth.
Synonym:
PP 242; 1092351-67-1; PP242; 2-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol; 2-[4-Amino-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol
CAS No.:
1092351-67-1
Compound CID:
135565635
Formula:
C16H16N6
Formula Weight:
308.34
Specification
Relative Density:
1.55 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Torkinib can be used in cancer cell biology studies or play an important role in cell growth regulation studies.
Library Information
Targets:
Kinases
Receptors:
mTORC1; mTORC2; p110δ
Pathways:
Autophagy; Apoptosis; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-7
Plate Location:
b4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 178.37 mM
ALogP:
2.908
HBA_Count:
3
HBD_Count:
3
Rotatable Bond:
2
